Home » Stocks » ALT

Altimmune, Inc. (ALT)

Stock Price: $13.59 USD 0.66 (5.10%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Pre-market: $13.63 +0.04 (0.29%) Jan 20, 8:50 AM
Market Cap 501.43M
Revenue (ttm) 6.45M
Net Income (ttm) -42.52M
Shares Out 33.06M
EPS (ttm) -2.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $13.59
Previous Close $12.93
Change ($) 0.66
Change (%) 5.10%
Day's Open 13.24
Day's Range 12.90 - 13.87
Day's Volume 1,133,584
52-Week Range 1.69 - 33.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - January 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such invest...

The Motley Fool - 1 week ago

Transport and storage of their potential vaccines would be a piece of cake.

Other stocks mentioned: VXRT
The Motley Fool - 2 weeks ago

This biotech just might have what it takes.

PRNewsWire - 2 weeks ago

NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such investors are advised to ...

The Motley Fool - 2 weeks ago

They're risky but could deliver huge returns in the new year.

Other stocks mentioned: NVAX, VXRT
Zacks Investment Research - 2 weeks ago

Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.

Benzinga - 2 weeks ago

Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B....

Other stocks mentioned: BCDA, INCY
GlobeNewsWire - 3 weeks ago

GAITHERSBURG, Md., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its mu...

The Motley Fool - 3 weeks ago

It's down, but not out.

Seeking Alpha - 3 weeks ago

Biotechvalley Insights is upgrading ALT's rating to "Very Bullish" from a "Bullish" rating with a 12 month TP of US$52. Altimmune's (ALT) valuation is at a discount after the recent sell-off, ...

24/7 Wall Street - 3 weeks ago

Altimmune Inc. (NASDAQ: ALT) shares dropped on Thursday after the company announced that it had received an update from the U.S.

Business Insider - 3 weeks ago

Altimmune, a clinical-stage biopharmaceutical company, fell as much as 10% on Thursday after the FDA issued a clinical hold on the company's COVID-19 vaccine candidate. AdCOVID is a single-dos...

GlobeNewsWire - 3 weeks ago

GAITHERSBURG, Md., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...

The Motley Fool - 1 month ago

Investors are excited about an analyst's bullish opinion about the biotech stock.

GlobeNewsWire - 1 month ago

GAITHERSBURG, Md., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer of ...

Seeking Alpha - 1 month ago

Share price has recently stumbled due to results of the leading vaccines. Vaccine development timeline is way behind the leading vaccines.

Zacks Investment Research - 1 month ago

Altimmune (ALT) files a regulatory application to begin a phase I study in the United States on AdCOVID, its intranasal COVID-19 vaccine candidate. Stock rises.

GlobeNewsWire - 1 month ago

Simple, single-dose nasal spray offers greater ease and comfort of administration ;  positioning AdCOVID as a differentiated vaccine candidate for adults and children

GlobeNewsWire - 2 months ago

GAITHERSBURG, Md., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutic...

Seeking Alpha - 2 months ago

Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2020 Results - Earnings Call Transcript

24/7 Wall Street - 2 months ago

Altimmune Inc. (NASDAQ: ALT) stepped forward on Tuesday with its vaccine candidate for COVID-19.

GlobeNewsWire - 2 months ago

AdCOVID , a Single-dose Intranasal Vaccine for COVID-19 is Designed to Generate a Broad Immune Response Against COVID-19 with the Unique Ability to Promote Nasal Mucosal Immunity

GlobeNewsWire - 2 months ago

GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ...

GlobeNewsWire - 2 months ago

GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 fina...

The Motley Fool - 3 months ago

A preprint is sending the biotech's shares higher today.

CNBC Television - 3 months ago

Altimmune CEO Vipin Garg with the latest on a potential inhaled vaccine

CNBC's Meg Tirrell on coronavirus cases rising. And Vipin Garg, Altimmune CEO, discusses the prospects for his company's inhaled vaccine.

GlobeNewsWire - 3 months ago

Comprehensive analysis shows AdCOVID uniquely stimulates three key immune compon ents: serum neutralizing antibody , T cell responses , and mucosal immunity in the respiratory tract

The Motley Fool - 3 months ago

In the race for a vaccine, a pause in progress sets you back.

Other stocks mentioned: CVAC, VBIV
GlobeNewsWire - 3 months ago

GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following u...

GlobeNewsWire - 3 months ago

GAITHERSBURG, Md., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Scot Roberts, Ph.D., Chief Scientific Of...

The Motley Fool - 3 months ago

An analyst's buy recommendation fueled investors' enthusiasm about the biotech stock.

Seeking Alpha - 4 months ago

Altimmune: The Late Bloomer Of The COVID-19 Biotech World, The Best Is Yet To Come

The Motley Fool - 4 months ago

Each of these biotech stocks has more than tripled year to date and could still have plenty of room to run.

Other stocks mentioned: INO, VXRT
The Motley Fool - 4 months ago

These biotechs are developing coronavirus vaccines with a twist.

Other stocks mentioned: VXRT
The Motley Fool - 4 months ago

Just follow these three simple steps.

Other stocks mentioned: AZN, INO, JNJ, MRNA, NVAX, PFE, VXRT
GlobeNewsWire - 4 months ago

Company anticipates first-in-human trials to start in Q4 2020 Company anticipates first-in-human trials to start in Q4 2020

The Motley Fool - 4 months ago

It's not a surprise that all five of these stocks are engaged in the fight against the novel coronavirus.

Other stocks mentioned: CODX, IBIO, NVAX, VXRT
The Motley Fool - 4 months ago

Some investors appear to be taking profits off the table with the high-flying biotech stock.

GlobeNewsWire - 4 months ago

GAITHERSBURG, Md., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced a preclinical data presentation on ALT-801, it...

GlobeNewsWire - 4 months ago

Antigen-specific CD4+ and CD8+ T cell responses in the lung not previously shown with advanced COVID-19 vaccine candidates Antigen-specific CD4+ and CD8+ T cell responses in the lung not previ...

The Motley Fool - 5 months ago

It’s tough to top quadruple-digit growth.

Other stocks mentioned: NVAX, VXRT
Seeking Alpha - 5 months ago

Altimmune, Inc. (ALT) CEO Vipin Garg on Q2 2020 Results - Earnings Call Transcript

InvestorPlace - 5 months ago

Altimmune earnings from Tuesday evening have ALT stock higher despite the company reporting rough figures for second quarter of FY2020. The post Altimmune Earnings: ALT Stock Rises 7% Despite ...

Benzinga - 5 months ago

Shares of Altimmune (NASDAQ:ALT) fell 2.38% in after-market trading after the company reported Q2 results.

GlobeNewsWire - 5 months ago

GAITHERSBURG, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months...

CNBC Television - 5 months ago

Altimmune CEO on Covid-19 vaccine and treatment, which involves a nasal spray

Altimmune CEO Vipin Garg discusses the progress of his company's coronavirus vaccine, which is administered through the nasal passages.

GlobeNewsWire - 5 months ago

GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase ...

GlobeNewsWire - 5 months ago

GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the ...

The Motley Fool - 5 months ago

Here's what drove shares of these healthcare stocks through the roof last month.

Other stocks mentioned: ABUS, OMI
GlobeNewsWire - 5 months ago

GAITHERSBURG, Md., July 22, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company has entered into an agreement...

About ALT

Altimmune, a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVI... [Read more...]

Industry
Biotechnology
CEO
Vipin Garg
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
ALT
Full Company Profile

Financial Performance

In 2019, Altimmune's revenue was $5.80 million, a decrease of -43.85% compared to the previous year's $10.33 million. Losses were -$20.52 million, -47.61% less than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Altimmune stock is "Strong Buy." The 12-month stock price forecast is 41.40, which is an increase of 204.64% from the latest price.

Price Target
$41.40
(204.64% upside)
Analyst Consensus: Strong Buy